Unknown

Dataset Information

0

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.

ABSTRACT:

SUBMITTER: Corti C 

PROVIDER: S-EPMC8103530 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.

Corti C C   Criscitiello C C  

ESMO open 20210303 2

Similar Datasets

Unknown Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.
| S-EPMC8164963 | biostudies-literature
Unknown FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
| S-EPMC9012688 | biostudies-literature
Unknown Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
| S-EPMC6143009 | biostudies-literature
Unknown The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis.
| S-EPMC9953803 | biostudies-literature
Unknown FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
| S-EPMC7356706 | biostudies-literature
Unknown FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
| S-EPMC11530298 | biostudies-literature
Unknown Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.
| S-EPMC10102835 | biostudies-literature
Unknown Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer.
| S-EPMC7817741 | biostudies-literature
Unknown Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.
| S-EPMC10578436 | biostudies-literature
Unknown Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.
| S-EPMC12363031 | biostudies-literature